Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal L Oden

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
JAMA Ophthalmology|October 28, 2021
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical TrialAhmad A Aref, Ingrid U Scott, Paul C VanVeldhuisen, et al.
Ophthalmology|April 7, 2009
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion typeIngrid U Scott, Barbara A Blodi, Michael S Ip, et al.
Ophthalmology|November 20, 2016
SCORE2 Report 2: Study Design and Baseline CharacteristicsIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
JAMA Ophthalmology|May 11, 2023
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialSteven M Kymes, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology|March 29, 2011
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusionClement K Chan, Michael S Ip, Paul C Vanveldhuisen, et al.
Ophthalmology|July 22, 2009
SCORE Study report 3: study design and baseline characteristicsMichael S Ip, Neal L Oden, Ingrid U Scott, et al.
American Journal of Ophthalmology|August 24, 2020
SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical TrialsAndrew Hendrick, Paul C VanVeldhuisen, Ingrid U Scott, et al.
JAMA Ophthalmology|June 7, 2019
Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical TrialIngrid U Scott, Paul C VanVeldhuisen, Franca Barton, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 12, 2012
Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14Ingrid U Scott, Paul C Vanveldhuisen, Neal L Oden, et al.
Ophthalmology. Retina|July 29, 2021
Cluster Analysis and Genotype-Phenotype Assessment of Geographic Atrophy in Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report 25Tiarnan D L Keenan, Neal L Oden, Elvira Agrón, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
JAMA Ophthalmology|October 28, 2021
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical TrialAhmad A Aref, Ingrid U Scott, Paul C VanVeldhuisen, et al.
Ophthalmology|April 7, 2009
SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion typeIngrid U Scott, Barbara A Blodi, Michael S Ip, et al.
Ophthalmology|November 20, 2016
SCORE2 Report 2: Study Design and Baseline CharacteristicsIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
JAMA Ophthalmology|May 11, 2023
Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 TrialSteven M Kymes, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology|March 29, 2011
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusionClement K Chan, Michael S Ip, Paul C Vanveldhuisen, et al.
Ophthalmology|July 22, 2009
SCORE Study report 3: study design and baseline characteristicsMichael S Ip, Neal L Oden, Ingrid U Scott, et al.
American Journal of Ophthalmology|August 24, 2020
SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes With Central or Hemiretinal Vein Occlusion Managed With Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical TrialsAndrew Hendrick, Paul C VanVeldhuisen, Ingrid U Scott, et al.
JAMA Ophthalmology|June 7, 2019
Patient-Reported Visual Function Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical TrialIngrid U Scott, Paul C VanVeldhuisen, Franca Barton, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|December 12, 2012
Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14Ingrid U Scott, Paul C Vanveldhuisen, Neal L Oden, et al.
Ophthalmology. Retina|July 29, 2021
Cluster Analysis and Genotype-Phenotype Assessment of Geographic Atrophy in Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report 25Tiarnan D L Keenan, Neal L Oden, Elvira Agrón, et al.
Pageof 6